Conference day two (Thursday 23rd February)
08:00
The recent introduction of the anti-TNF biosimilars, infliximab and etanercept, has attracted considerable attention, with a focus on how competitive discounting will impact branded manufacturers’ revenue streams and drive cost-savings for healthcare systems. Interest is now turning to the next wave of biosimilars due to launch in Europe: oncologic biosimilars. Monoclonal antibody (mAb) treatments such as rituximab, trastuzumab and cetuximab have already reached loss of exclusivity in EU and recently the EMA accepted two biosimilar products for regulatory review: rituximab and trastuzumab. These products are expected to launch later this year, with biosimilar cetuximab due to follow in 2018. In this Breakfast Briefing, we will present the outcomes of our most recent research, supported by 15 qualitative in-depth interviews with national and regional payers across EU5 markets. Our research explore the following:
- Discount expectations for oncology biosimilars and likely payer management
- Impact of oncology biosimilars on access and uptake of other branded treatments
- Opportunities and challenges for new innovative products launching in a space dominated by oncology biosimilars
Breakfast briefing led by Precision for Value:The impact of oncology biosimilars in the pricing and market access potential of innovative products
The recent introduction of the anti-TNF biosimilars, infliximab and etanercept, has attracted considerable attention, with a focus on how competitive discounting will impact branded manufacturers’ revenue streams and drive cost-savings for healthcare systems. Interest is now turning to the next wave of biosimilars due to launch in Europe: oncologic biosimilars. Monoclonal antibody (mAb) treatments such as rituximab, trastuzumab and cetuximab have already reached loss of exclusivity in EU and recently the EMA accepted two biosimilar products for regulatory review: rituximab and trastuzumab. These products are expected to launch later this year, with biosimilar cetuximab due to follow in 2018. In this Breakfast Briefing, we will present the outcomes of our most recent research, supported by 15 qualitative in-depth interviews with national and regional payers across EU5 markets. Our research explore the following:
- Discount expectations for oncology biosimilars and likely payer management
- Impact of oncology biosimilars on access and uptake of other branded treatments
- Opportunities and challenges for new innovative products launching in a space dominated by oncology biosimilars
09:00
Risk share, innovative contracting and value based assessments with new medicines
09:30
Maintaining value of our data and managing patient access effectively
10:00
Scottish Health Intelligence – Creating value for the world
10:20
Morning refreshments
Panel discussion: How can we work better for the patient?
11:45
When science is not enough: developing an evidence-based framework for more customer-focused drug development
12:05
Exploring the role of evidence in formulating technology intensive health programs
12:25
Katja Rüdell, Director, Patient Reported Outcomes,AstraZeneca
13:55
Integrative care access models: healthcare disrupted from selling pills to selling value
14:15
COMET Initiative and Standardising Outcomes
14:35
1 year on - Japan and HTA pilot project
- Update on Market Access in Japan
- Role of RWE in Japanese HTA
14:55
The importance of post-marketing registries for payers and regulators to manage drug pricing and conditional reimbursement
Ms Entela Xoxi, Pharmacologist Adviser, Italian Medicines Agency
last published: 20/Feb/17 12:35 GMT
